

18<sup>th</sup> Joint event on

# EUROPEAN OPHTHALMOLOGY CONGRESS & OCULAR PHARMACOLOGY

December 04-06, 2017 | Rome, Italy

## Glaucoma in patients with Parkinson's disease: What can a screening event reveal?

Kanonidou E, Karagiannidis Stampoulis G, Kalouda P, Lakidis N, Kamaras G and Balatsoukas D  
Hippokraton General Hospital of Thessaloniki, Greece

**Statement of the problem:** To evaluate the outcomes of a glaucoma vision screening event of patients with Parkinson's disease undertaken in our practice.

**Methodology & Theoretical Orientation:** Semi-automated equipment for measurement of intraocular pressure (IOP) (portable rebound tonometer iCare) and handheld digital retinal camera for non-mydratic eye fundus examination (EY3 optomed smartscope M5) were used for screening. An experienced glaucoma specialist evaluated the outcome measures. A questionnaire was used to assess participants knowledge of glaucoma's symptoms and detection.

**Findings:** 71 patients (54 males) with Parkinsons disease, mean age 66.76 years old, no ocular comorbidities, participated in screening. 10 had IOP>21mmHg in both eyes and 22 had cup/disc (c/d) ratio>0.5 or c/d ratio asymmetry between eyes. 20 visited an Ophthalmologist rarely (every five years) or never. 49 had no understanding of glaucoma. 63 had no knowledge about glaucoma initial symptoms and risk factors; only 4 recognized heredity as risk factor. Only 4 mentioned tonometry as a method of glaucoma detection and 4 mentioned funduscopy.

**Conclusion & Significance:** Our results seem to agree with recent findings, which indicate that glaucoma is associated with Parkinson and other neurodegenerative diseases. Targeted vision screening programmes can provide valuable information to patients about the management of their eye problems.